GENP Share Price

Open 47.02 Change Price %
High 49.84 1 Day 0.00 0.00
Low 46.03 1 Week 0.00 0.00
Close 48.28 1 Month 0.00 0.00
Volume 2583 1 Year 0.00 0.00
52 Week High 99.68
52 Week Low 72.00
GENP Important Levels
Resistance 2 51.81
Resistance 1 50.36
Pivot 48.05
Support 1 46.20
Support 2 44.75
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
AF 6.46 4.53%
AF 6.46 4.53%
More..
EPA France Top Gainers Stocks
ITXT 3.04 35.11%
MLMGL 8.00 29.03%
MLWEY 2.50 26.26%
ALADO 0.07 16.67%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
ALALO 0.04 -20.00%
FLO 1.08 -16.28%
FLO 1.08 -16.28%
ALLOG 0.97 -12.61%
JXR 1.31 -11.49%
MLSAT 1.13 -8.87%
CGD 71.20 -5.07%
CGD 71.20 -5.07%
CGD 71.20 -5.07%
MLFXO 4.50 -4.26%
More..

Stallergènes SA (EPA: GENP)

GENP Technical Analysis 5
As on 7th Sep 2015 GENP Share Price closed @ 48.28 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 53.10 & Strong Sell for SHORT-TERM with Stoploss of 54.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
GENP Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
GENP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.stallergenes.fr
GENP Address
GENP
6, rue Alexis de Tocqueville
CS 10032
Antony, 92183
France
Phone: 33 1 55 59 20 00
Fax: 33 1 55 59 21 68
GENP Latest News
Stallergenes Greer Announces Positive Top-Line Results of Phase 3 Study for ...   Business Wire (press release)   - 27th Jan 17
Stallergenes Greer Announces Its 2015 Full Year Results   Business Wire (press release)   - 27th Apr 16
Stallergenes Greer Announces Resumption of Manufacturing at Its Antony, France ...   Business Wire (press release)   - 01st Feb 16
Stallergenes-Greer Takeover Getting Messy   Seeking Alpha   - 10th Apr 15
BRIEF-Stallergenes announces proposal to merge with Greer Laboratories   Reuters   - 04th Mar 15
Laboratories, Inc. and STALLERGENES Sign Exclusive Agreement for United States ...   Business Wire (press release)   - 31st Oct 13
Stallergenes and Shionogi Sign Exclusive Partnership Agreements for ...   PR Newswire (press release)   - 07th Sep 10
Stallergenes: Staloral(R) Mites 300 Clinical Study in China: Efficacy is ...   PR Newswire (press release)   - 21st Jun 10
Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study   PR Newswire (press release)   - 07th Dec 09
Stallergenes and Paladin Labs Sign a Partnership for Oralair (TM) in Canada   PR Newswire UK (press release)   - 09th Jan 07
Interactive Technical Analysis Chart Stallergènes SA ( GENP EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Stallergènes SA
GENP Business Profile
Stallergenes S.A., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of allergen immunotherapy treatments against severe respiratory allergies in France. It is involved in the pharmaceutical and clinical development program Stalair, a pharmaceutical specialty covering severe respiratory allergies, such as severe rhino conjunctivitis and rhinitis; allergic asthma; and various respiratory allergies. The company’s products include Oralair, an allergen immunotherapy tablet; Staloral, a sublingual solution; and subcutaneous route comprising Phostal and Alustal suspensions for injection of allergen extracts. Its products also comprise diagnosis products that consist of freeze-dried allergen extracts and diluents, such as Alyostal IDR products for intra-dermal reaction, Alyostal TPN products for the nasal provocation test, and Alyostal TPC products for the conjunctival provocation test; and Alyostal Prick products, which are glycerinated allergen extracts, as well as True Test, a transdermal skin patch test used to facilitate the diagnosis of allergens that induce contact dermatitis. The company, through its subsidiaries, distributes its products in approximately 50 countries. Stallergenes S.A. was founded in 1962 and is based in Antony, France.